Browse ICE1

Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, Cajal body Note=Colocalizes with COIL in subnuclear Cajal and histone locus bodies. Associates to transcriptionally active chromatin at snRNA genes.
Domain -
Function

Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:22195968, PubMed:23932780). Specifically acts as a scaffold protein that promotes the LEC complex formation and recruitment and RNA polymerase II occupancy at snRNA genes in subnuclear bodies (PubMed:23932780).

> Gene Ontology
 
Biological Process GO:0006359 regulation of transcription from RNA polymerase III promoter
GO:0006383 transcription from RNA polymerase III promoter
GO:0009301 snRNA transcription
GO:0016073 snRNA metabolic process
GO:0031334 positive regulation of protein complex assembly
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0042796 snRNA transcription from RNA polymerase III promoter
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045945 positive regulation of transcription from RNA polymerase III promoter
GO:0051222 positive regulation of protein transport
GO:0090316 positive regulation of intracellular protein transport
GO:0098781 ncRNA transcription
GO:1903829 positive regulation of cellular protein localization
GO:1904951 positive regulation of establishment of protein localization
Molecular Function -
Cellular Component GO:0000785 chromatin
GO:0008023 transcription elongation factor complex
GO:0015030 Cajal body
GO:0016604 nuclear body
GO:0035327 transcriptionally active chromatin
GO:0035363 histone locus body
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ICE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ICE1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.39; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ICE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2040.594
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1550.93
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3080.871
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1030.914
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6890.59
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1140.0857
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ICE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ICE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ICE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ICE1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ICE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ICE1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ICE1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolICE1
Nameinteractor of little elongation complex ELL subunit 1
Aliases KIAA0947; interactor of little elongator complex ELL subunit 1; Little elongation complex subunit 1
Chromosomal Location5p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ICE1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.